Citigroup’s HCW Biologics HCWB Stock Holding History

Citigroup’s Portfolio HCWB Stock Details HCWB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,755	Closed	-$3.79K	–	5955
2026 Q1	$3.79K	Buy	+1,755	New	+$9.07K	﹤0.01%	5314
2025 Q4	–	Sell	-52	Closed	-$884	–	5971
2025 Q3	$1.15K	Buy	+52	New	+$1.36K	﹤0.01%	5606
2025 Q2	–	Sell	-59	Closed	-$3.96K	–	5756
2025 Q1	$3.96K	Buy	+59	New	+$5.19K	﹤0.01%	5299

Other funds holding HCWB

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup's HCWB Position: Q2 2026 in Review

Citigroup sold out of HCW Biologics (HCWB) in Q2 2026, closing a stake of 1,755 shares — an estimated $3.79K sold.

Citigroup first reported a position in HCWB in Q1 2025 and held it in 3 quarters. The position peaked at $3.96K in Q1 2025. 7 funds tracked by Wall St. Rank hold HCWB as of Q2 2026.

Citigroup reported no remaining HCW Biologics position as of Q2 2026 after selling out during the quarter.
Citigroup sold 1,755 HCW Biologics shares in Q2 2026, an estimated $3.79K.
Citigroup first reported a position in HCW Biologics in Q1 2025 and held it in 3 quarters.
Citigroup's HCW Biologics position peaked at $3.96K in Q1 2025.
7 funds tracked by Wall St. Rank held HCW Biologics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.